Investors may be wondering if Taysha Gene Therapies at around $5.49 is still a smart bet after its big rebound, or if the easy money has already been made. The stock is down 4.7% over the last week, ...
A new study suggests that dementia may be driven in part by faulty blood flow in the brain. Researchers found that losing a ...
Despite a Trump administration push, there are few facilities offering the complex treatment in the rural areas where many ...
"Swearing is an easily available way to help yourself feel focused, confident and less distracted, and 'go for it' a little ...
Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...
BHOPAL: Genetic science researchers from across the country have turned their focus to genomic factors that may underlie the ...
Most pet dogs carry a little wolf inside them; tiny snippets of wolf DNA that slipped into dog genomes after domestication. A new study, published in Proceedings of the National Academy of Sciences, ...
Dhurandhar actor Akshaye Khanna opens up about hair loss at 19. Here's what triggers premature balding and why it’s not always genetic. TheHealthSite.com ...
If you are wondering whether Natera's share price still makes sense after such a big run, you are not alone. This breakdown is designed to help you decide if the current price offers genuine value or ...
The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...
Studies show a partial-match bone marrow transplant is rewriting the future for sickle cell patients, with survival rates ...
He added, "You might be a sportsman, a cricketer or a footballer, and realise that you might need knee surgery. So it's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback